Qsymia requires to be taken as an adjunct to a reduced-calorie diet and increased physical activity for obesity management by patients with improper body mass index along with hypertension, type 2 diabetes mellitus, which are weight-related comorbidities.
Vivus president Peter Tam said the company heading forward in effectively treating obesity, which has serious health consequences.
"We are excited about making this new treatment option available to patients because Qsymia is the first FDA-approved oral medication that has been shown to achieve an average weight loss of 10% in obese patients when used in conjunction with a lifestyle modification program," Tam added.
The company, in order to ensure safe usage of Qsymia by healthcare providers and patients, has initiated a product usage program called ‘Qsymia Risk Evaluation and Mitigation Strategy (REMS)’.
Vivus said Qsymia is available only through certified mail order pharmacies, which are part of the Qsymia Home Delivery Network including CVS Pharmacy and Walgreens.
Obesity Action Coalition president and CEO Joe Nadglowski said, "With the availability of this new therapeutic option, Americans struggling with obesity finally have another important tool to help address their weight and related co-morbidities."